Structural magnetic resonance imaging-derived biomarkers for Alzheimer's disease.

The development and validation of biomarkers for prediction, diagnosis and tracking of progression of Alzheimer's disease are both increasingly important. As potential pharmaceutical agents are developed for Alzheimer's disease, their efficacy needs to be assessed. When medications become available, those subjects who may derive most benefit from such treatments need to be selected and their response to treatment monitored. As such, there has been much research into biomarkers in recent years, with many showing promise in all areas of biomarker utility. This review focuses on the potential of structural imaging as a biomarker in Alzheimer's disease.

[1]  Xin Yu,et al.  Randomized, placebo-controlled trial of the effects of donepezil on neuronal markers and hippocampal volumes in Alzheimer's disease. , 2003, The American journal of psychiatry.

[2]  C R Jack.  Brain and cerebrospinal fluid volume: measurement with MR imaging. , 1991, Radiology.

[3]  Bruce L. Miller,et al.  Appendix B: Practice parameter: Diagnosis of dementia (an evidence-based review): Report of the quality standards subcommittee of the American academy neurology , 2007 .

[4]  G. Frisoni,et al.  Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer’s disease , 1999, Neurology.

[5]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[6]  J. Morris,et al.  Validation of clinical diagnostic criteria for Alzheimer's disease , 1988, Annals of neurology.

[7]  A. Toga,et al.  Hippocampal Atrophy in Persons With Age-Associated Memory Impairment: Volumetry Within a Common Space , 2002, Psychosomatic medicine.

[8]  H Soltanian-Zadeh,et al.  Segmentation of the hippocampus from brain MRI using deformable contours. , 1998, Computerized medical imaging and graphics : the official journal of the Computerized Medical Imaging Society.

[9]  M N Rossor,et al.  Patterns of temporal lobe atrophy in semantic dementia and Alzheimer's disease , 2001, Annals of neurology.

[10]  Henry Rusinek,et al.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. , 2003, Radiology.

[11]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[12]  C. Jack,et al.  Comparison of different MRI brain atrophy rate measures with clinical disease progression in AD , 2004, Neurology.

[13]  G. Frisoni,et al.  Medial temporal atrophy but not memory deficit predicts progression to dementia in patients with mild cognitive impairment , 2006, Journal of Neurology, Neurosurgery & Psychiatry.

[14]  C. Mathers,et al.  Global prevalence of dementia: a Delphi consensus study , 2005, The Lancet.

[15]  N. Schuff,et al.  Comparison of automated and manual MRI volumetry of hippocampus in normal aging and dementia , 2002, Journal of magnetic resonance imaging : JMRI.

[16]  J V Hajnal,et al.  Serial brain MRI at 3-6 month intervals as a surrogate marker for Alzheimer's disease. , 2002, The British journal of radiology.

[17]  Michael I. Miller,et al.  Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging☆ , 2003, NeuroImage.

[18]  R. Petersen,et al.  Mild cognitive impairment , 2006, The Lancet.

[19]  Vladimir Kepe,et al.  Seeing is believing: neuroimaging adds to our understanding of cerebral pathology , 2006, Current opinion in psychiatry.

[20]  Nick C. Fox,et al.  The boundary shift integral: an accurate and robust measure of cerebral volume changes from registered repeat MRI , 1997, IEEE Transactions on Medical Imaging.

[21]  C. Jack,et al.  Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI , 2005, Neurology.

[22]  J. Morris,et al.  Current concepts in mild cognitive impairment. , 2001, Archives of neurology.

[23]  Paul M. Thompson,et al.  In vivo neuropathology of the hippocampal formation in AD: A radial mapping MR-based study , 2006, NeuroImage.

[24]  Nick C Fox,et al.  Mapping the evolution of regional atrophy in Alzheimer's disease: Unbiased analysis of fluid-registered serial MRI , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[25]  N. Schuff,et al.  Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia , 2003, Neurobiology of Aging.

[26]  Nick C Fox,et al.  Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease , 2005, Neurology.

[27]  Stephen M. Smith,et al.  Accurate, Robust, and Automated Longitudinal and Cross-Sectional Brain Change Analysis , 2002, NeuroImage.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[29]  Alan C. Evans,et al.  Automated cortical thickness measurements from MRI can accurately separate Alzheimer's patients from normal elderly controls , 2008, Neurobiology of Aging.

[30]  C. Jack,et al.  Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. , 2007, Archives of neurology.

[31]  C. Jack,et al.  MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD , 2003, Neurology.

[32]  Gwenn S. Smith,et al.  EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUS , 1989, The Lancet.

[33]  Hiroko H Dodge,et al.  Functional transitions and active life expectancy associated with Alzheimer disease. , 2003, Archives of neurology.

[34]  M. Albert,et al.  MRI measures of entorhinal cortex vs hippocampus in preclinical AD , 2002, Neurology.

[35]  S. Wisniewski,et al.  Research evaluation and diagnosis of possible Alzheimer’s disease over the last two decades: II , 2000, Neurology.

[36]  Paul M. Thompson,et al.  Mapping hippocampal and ventricular change in Alzheimer disease , 2004, NeuroImage.

[37]  Nick C Fox,et al.  Modeling brain deformations in Alzheimer disease by fluid registration of serial 3D MR images. , 1998, Journal of computer assisted tomography.

[38]  R. Mayeux.  Evaluation and Use of Diagnostic Tests in Alzheimer’s Disease , 1998, Neurobiology of Aging.

[39]  S Lehéricy,et al.  Amygdalohippocampal MR volume measurements in the early stages of Alzheimer disease. , 1994, AJNR. American journal of neuroradiology.

[40]  Nick C Fox,et al.  Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study , 2006, The Lancet Neurology.

[41]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[42]  Nick C Fox,et al.  Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias. , 2005, Archives of neurology.

[43]  Richard Camicioli,et al.  Independent predictors of cognitive decline in healthy elderly persons. , 2002, Archives of neurology.

[44]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[45]  J. Quinn,et al.  Changes in premorbid brain volume predict Alzheimer’s disease pathology , 2003, Neurology.

[46]  P. Scheltens,et al.  Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[47]  C. Jack,et al.  Rates of hippocampal atrophy correlate with change in clinical status in aging and AD , 2000, Neurology.

[48]  Hiroaki Kazui,et al.  Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? , 2005, The American journal of psychiatry.

[49]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[50]  J. Masdeu,et al.  Neuroimaging as a marker of the onset and progression of Alzheimer's disease , 2005, Journal of the Neurological Sciences.

[51]  Gene E. Alexander,et al.  Volumes of Medial Temporal Lobe Structures in Patients with Alzheimer’s Disease and Mild Cognitive Impairment (and in Healthy Controls) , 1998, Biological Psychiatry.

[52]  Lei Wang,et al.  Neuroanatomical predictors of response to donepezil therapy in patients with dementia. , 2005, Archives of neurology.

[53]  Alain Pitiot,et al.  Expert knowledge-guided segmentation system for brain MRI , 2003, NeuroImage.

[54]  Antonio Federico,et al.  Cerebrospinal fluid tau, Aß, and phosphorylated tau protein for the diagnosis of Alzheimer's disease , 2006, Journal of cellular physiology.

[55]  W R Markesbery,et al.  An automated technique for measuring hippocampal volumes from MR imaging studies. , 2001, AJNR. American journal of neuroradiology.

[56]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[57]  M N Rossor,et al.  Measuring atrophy in Alzheimer disease , 2005, Neurology.

[58]  Randall S. Jones,et al.  1H-MRS evaluation of metabolism in Alzheimer's disease and vascular dementia , 2004, Neurological research.

[59]  V. Hachinski,et al.  A NEW DEFINITION OF ALZHEIMER'S DISEASE: A HIPPOCAMPAL DEMENTIA , 1985, The Lancet.

[60]  Nick C Fox,et al.  Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.

[61]  Tuomo Hänninen,et al.  Diagnosis of Alzheimer’s disease: MRI of the hippocampus vs delayed recall , 2000, Neuropsychologia.

[62]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[63]  Hilkka Soininen,et al.  Hippocampus in Alzheimer’s disease: a 3-year follow-up MRI study , 2000, Biological Psychiatry.

[64]  Kiralee M. Hayashi,et al.  Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.

[65]  J. Baron,et al.  In Vivo Mapping of Gray Matter Loss with Voxel-Based Morphometry in Mild Alzheimer's Disease , 2001, NeuroImage.

[66]  C. Jack,et al.  Usefulness of MRI measures of entorhinal cortex versus hippocampus in AD , 2000, Neurology.

[67]  E. Tangalos,et al.  Mild Cognitive Impairment Clinical Characterization and Outcome , 1999 .

[68]  N. Schuff,et al.  Magnetic resonance imaging of the entorhinal cortex and hippocampus in mild cognitive impairment and Alzheimer's disease , 2001, Journal of neurology, neurosurgery, and psychiatry.

[69]  Jeffrey L. Cummings,et al.  Practice parameter: Diagnosis of dementia (an evidence-based review) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[70]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[71]  Martin Rossor,et al.  Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration. , 2006, Archives of neurology.

[72]  S. Joshi,et al.  Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus , 2000, Neurology.

[73]  N. Schuff,et al.  Higher atrophy rate of entorhinal cortex than hippocampus in AD , 2004, Neurology.

[74]  J. Kaye,et al.  Asynchronous regional brain volume losses in presymptomatic to moderate AD. , 2005, Journal of Alzheimer's disease : JAD.

[75]  H. Braak,et al.  Staging of Alzheimer-related cortical destruction. , 1997, International psychogeriatrics.

[76]  C. Jack,et al.  Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease , 1998, Neurology.

[77]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.